6625. Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants.
作者: Krystian Kozek.;Yuko Wada.;Luca Sala.;Isabelle Denjoy.;Christian Egly.;Matthew J O'Neill.;Takeshi Aiba.;Wataru Shimizu.;Naomasa Makita.;Taisuke Ishikawa.;Lia Crotti.;Carla Spazzolini.;Maria-Christina Kotta.;Federica Dagradi.;Silvia Castelletti.;Matteo Pedrazzini.;Massimiliano Gnecchi.;Antoine Leenhardt.;Joe-Elie Salem.;Seiko Ohno.;Yi Zuo.;Andrew M Glazer.;Jonathan D Mosley.;Dan M Roden.;Bjorn C Knollmann.;Jeffrey D Blume.;Fabrice Extramiana.;Peter J Schwartz.;Minoru Horie.;Brett M Kroncke.
来源: Circ Genom Precis Med. 2021年14卷4期e003289页
The proliferation of genetic profiling has revealed many associations between genetic variations and disease. However, large-scale phenotyping efforts in largely healthy populations, coupled with DNA sequencing, suggest variants currently annotated as pathogenic are more common in healthy populations than previously thought. In addition, novel and rare variants are frequently observed in genes associated with disease both in healthy individuals and those under suspicion of disease. This raises the question of whether these variants can be useful predictors of disease. To answer this question, we assessed the degree to which the presence of a variant in the cardiac potassium channel gene KCNH2 was diagnostically predictive for the autosomal dominant long QT syndrome.
6626. Impact of Mitral Annular Dilation on Edge-to-Edge Therapy With MitraClip-XTR.
作者: Felix Kreidel.;Syed Zaid.;Alexander R Tamm.;Tobias F Ruf.;Andres Beiras-Fernandez.;Jenny Reinold.;Martin Geyer.;Jaqueline da Rocha E Silva.;Katharina Schnitzler.;Hell Michaela.;Thomas Münzel.;Gilbert H L Tang.;Ralph Stephan von Bardeleben.
来源: Circ Cardiovasc Interv. 2021年14卷8期e010447页
[Figure: see text].
6627. Cirrhosis in a 42 Year Old With a History of Attempted Atrial Septal Defect Closure in Childhood.
作者: Graham Stockdale.;John P Breinholt.;Erik Ellsworth.;Nisha Bhatia.;Wayne J Franklin.;Jordan D Awerbach.
来源: Circ Cardiovasc Imaging. 2021年14卷8期e012903页 6628. Trajectories of Pain After Cardiac Surgery: Implications for Measurement, Reporting, and Individualized Treatment.
作者: Makoto Mori.;Cornell Brooks.;Sanket S Dhruva.;Yuan Lu.;Erica S Spatz.;Pranammya Dey.;Yawei Zhang.;Sarwat I Chaudhry.;Arnar Geirsson.;Heather G Allore.;Harlan M Krumholz.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷8期e007781页
Postoperative pain after cardiac surgery is a significant problem, but studies often report pain value as an average of the study cohort, obscuring clinically meaningful differences in pain trajectories. We sought to characterize heterogeneity in postoperative pain experiences.
6629. Considerations for Cardiovascular Genetic and Genomic Research With Marginalized Racial and Ethnic Groups and Indigenous Peoples: A Scientific Statement From the American Heart Association.
作者: Gia Mudd-Martin.;Allison L Cirino.;Veronica Barcelona.;Keolu Fox.;Maui Hudson.;Yan V Sun.;Jacquelyn Y Taylor.;Vicky A Cameron.; .
来源: Circ Genom Precis Med. 2021年14卷4期e000084页
Historically marginalized racial and ethnic groups and Indigenous peoples are burdened by significant health inequities that are compounded by their underrepresentation in genetic and genomic research. Of all genome-wide association study participants, ≈79% are of European descent, despite this group constituting only 16% of the global population. For underrepresented populations, polygenic risk scores derived from these studies are less accurate in predicting disease phenotypes, novel population-specific genetic variations may be misclassified as potentially pathogenic, and there is a lack of understanding of how different populations metabolize drugs. Although inclusion of marginalized racial and ethnic groups and Indigenous peoples in genetic and genomic research is crucial, scientific studies must be guided by ethical principles of respect, honesty, justice, reciprocity, and care for individuals and communities. Special considerations are needed to support research that benefits the scientific community as well as Indigenous peoples and marginalized groups. Before a project begins, collaboration with community leaders and agencies can lead to successful implementation of the study. Throughout the study, consideration must be given to issues such as implications of informed consent for individuals and communities, dissemination of findings through scientific and community avenues, and implications of community identity for data governance and sharing. Attention to these issues is critical, given historical harms in biomedical research that marginalized groups and Indigenous peoples have suffered. Conducting genetic and genomic research in partnership with Indigenous peoples and marginalized groups guided by ethical principles provides a pathway for scientific advances that will enhance prevention and treatment of cardiovascular disease for everyone.
6631. Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes.
作者: Sanjay Divakaran.;Brett J Carroll.;Siyan Chen.;Changyu Shen.;Marc P Bonaca.;Eric A Secemsky.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷8期e007953页 6632. Segment Length in Cine Strain Analysis Predicts Cardiac Resynchronization Therapy Outcome Beyond Current Guidelines.
作者: Alwin Zweerink.;Daniel J Friedman.;Igor Klem.;Peter M van de Ven.;Caitlin Vink.;P Stefan Biesbroek.;Steen M Hansen.;Raymond J Kim.;Albert C van Rossum.;Brett D Atwater.;Cornelis P Allaart.;Robin Nijveldt.
来源: Circ Cardiovasc Imaging. 2021年14卷7期e012350页
Patients with a class I recommendation for cardiac resynchronization therapy (CRT) are likely to benefit, but the effect of CRT in class II patients is more heterogeneous and additional selection parameters are needed in this group. The recently validated segment length in cine strain analysis of the septum (SLICE-ESSsep) measurement on cardiac magnetic resonance cine imaging predicts left ventricular functional recovery after CRT but its prognostic value is unknown. This study sought to evaluate the prognostic value of SLICE-ESSsep for clinical outcome after CRT.
6633. Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation.
作者: Brett D Atwater.;Zhen Li.;Jessica Pritchard.;Melissa A Greiner.;Yelena Nabutovsky.;Bradley G Hammill.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷8期e007580页
Increased physical activity (PA) through cardiac rehabilitation (CR) improves outcomes in patients with heart failure and coronary disease, but CR referral remains infrequent. Implantable cardioverter-defibrillators (ICDs) can provide daily PA measurements to patients that may motivate them to increase PA, but it remains unclear if increased ICD measured PA is associated with improved outcomes with and without CR.
6635. Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry.
作者: Benjamin A Satterfield.;Ozan Dikilitas.;Maya S Safarova.;Shoa L Clarke.;Catherine Tcheandjieu.;Xiang Zhu.;Lisa Bastarache.;Eric B Larson.;Anne E Justice.;Ning Shang.;Elisabeth A Rosenthal.;Amy Sanghavi Shah.;Bahram Namjou-Khales.;Elaine M Urbina.;Wei-Qi Wei.;QiPing Feng.;Gail P Jarvik.;Scott J Hebbring.;Mariza de Andrade.;Teri A Manolio.;Themistocles L Assimes.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2021年14卷4期e003354页
Lp(a) (lipoprotein [a]) levels are higher in individuals of African ancestry (AA) than in individuals of European ancestry (EA). We examined associations of genetically predicted Lp(a) levels with (1) atherosclerotic cardiovascular disease subtypes: coronary heart disease, cerebrovascular disease, peripheral artery disease, and abdominal aortic aneurysm and (2) nonatherosclerotic cardiovascular disease phenotypes, stratified by ancestry.
6636. Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry.
作者: Keiichiro Kuronuma.;Robert J H Miller.;Yuka Otaki.;Serge D Van Kriekinge.;Marcio A Diniz.;Tali Sharir.;Lien-Hsin Hu.;Heidi Gransar.;Joanna X Liang.;Tejas Parekh.;Paul B Kavanagh.;Andrew J Einstein.;Mathews B Fish.;Terrence D Ruddy.;Philipp A Kaufmann.;Albert J Sinusas.;Edward J Miller.;Timothy M Bateman.;Sharmila Dorbala.;Marcelo Di Carli.;Balaji K Tamarappoo.;Damini Dey.;Daniel S Berman.;Piotr J Slomka.
来源: Circ Cardiovasc Imaging. 2021年14卷7期e012386页
Phase analysis of single-photon emission computed tomography myocardial perfusion imaging provides dyssynchrony information which correlates well with assessments by echocardiography, but the independent prognostic significance is not well defined. This study assessed the independent prognostic value of single-photon emission computed tomography-myocardial perfusion imaging phase analysis in the largest multinational registry to date across all modalities.
6638. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events.
作者: Seung-Jun Lee.;Yong-Joon Lee.;Byeong-Keuk Kim.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.
来源: Circ Cardiovasc Interv. 2021年14卷8期e010812页
[Figure: see text].
6639. Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review.
作者: Yousif Eliya.;Sera Whitelaw.;Lehana Thabane.;Adriaan A Voors.;Pamela S Douglas.;Harriette G C Van Spall.
来源: Circ Heart Fail. 2021年14卷8期e008064页
Trial steering committees (TSCs) steer the conduct of randomized controlled trials (RCTs). We examined the gender composition of TSCs in impactful heart failure RCTs and explored whether trial leadership by a woman was independently associated with the inclusion of women in TSCs.
6640. Myocarditis With COVID-19 mRNA Vaccines.
Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations, especially in young adult and adolescent males. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are ≈12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age. In reported cases, patients with myocarditis invariably presented with chest pain, usually 2 to 3 days after a second dose of mRNA vaccination, and had elevated cardiac troponin levels. ECG was abnormal with ST elevations in most, and cardiac MRI was suggestive of myocarditis in all tested patients. There was no evidence of acute COVID-19 or other viral infections. In 1 case, a cardiomyopathy gene panel was negative, but autoantibody levels against certain self-antigens and frequency of natural killer cells were increased. Although the mechanisms for development of myocarditis are not clear, molecular mimicry between the spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and self-antigens, trigger of preexisting dysregulated immune pathways in certain individuals, immune response to mRNA, and activation of immunologic pathways, and dysregulated cytokine expression have been proposed. The reasons for male predominance in myocarditis cases are unknown, but possible explanations relate to sex hormone differences in immune response and myocarditis, and also underdiagnosis of cardiac disease in women. Almost all patients had resolution of symptoms and signs and improvement in diagnostic markers and imaging with or without treatment. Despite rare cases of myocarditis, the benefit-risk assessment for COVID-19 vaccination shows a favorable balance for all age and sex groups; therefore, COVID-19 vaccination is recommended for everyone ≥12 years of age.
|